COA6在乳腺癌中的表达及其与肿瘤免疫细胞浸润相关

doi:10.16352/j.issn.1001-6325.2025.06.0755

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (6): 755-761.doi: 10.16352/j.issn.1001-6325.2025.06.0755

COA6在乳腺癌中的表达及其与肿瘤免疫细胞浸润相关

金晓霞¹, 刘玉山¹, 胡继平², 朱兴华^1*

1.南通大学附属肿瘤医院病理科, 江苏南通 226000;
2.南通大学医学院临床病理系,江苏南通 226000

收稿日期:2024-12-12 修回日期:2025-02-24 出版日期:2025-06-05 发布日期:2025-05-26
通讯作者: ^*36529204@qq.com
基金资助:
南通市科技计划指令性项目(MS22022015)

Expression of COA6 in breast cancer and its correlation with tumor immune cell infiltration

JIN Xiaoxia¹, LIU Yushan¹, HU Jiping², ZHU Xinghua^1*

1. Department of Pathology, Tumor Hospital Affiliated to Nantong University, Nantong 226000;
2. Department of Clinical Pathology, Medical College, Nantong University, Nantong 226000, China

Received:2024-12-12 Revised:2025-02-24 Online:2025-06-05 Published:2025-05-26

摘要/Abstract

摘要： 目的检测细胞色素c氧化酶组装因子6(COA6)在乳腺癌中的表达及临床意义,分析COA6与乳腺癌免疫浸润的相关性。方法全转录组测序筛选差异基因,并联合TCGA数据库验证COA6的表达。免疫组化技术检测125例乳腺癌组织及癌旁组织COA6蛋白表达,分析其与临床特征的相关性。分别用qRT-PCR、Western blot检测乳腺癌细胞、组织中COA6 mRNA及蛋白表达。利用TIMER数据库分析COA6基因的高表达与免疫细胞浸润的关系。结果乳腺癌组织中COA6的阳性表达率为(88%, 110/125),显著高于癌旁组织(7.2%, 9/125)(P＜0.05),并且与肿瘤的大小和组织学分级呈正相关。在新鲜乳腺癌组织中,COA6蛋白的表达水平明显高于癌旁组织。在乳腺癌细胞系中,COA6 mRNA和蛋白表达均明显增加。COA6与辅助T细胞、NK细胞、CD8⁺ T细胞、M1型巨噬细胞、调节性T细胞、树突细胞、记忆性CD4⁺ T细胞在肿瘤微环境中的浸润有关。结论 COA6在乳腺癌中的表达水平升高,并且与肿瘤免疫浸润呈正相关,这为乳腺癌治疗提供了潜在的治疗靶点。

关键词: 细胞色素c氧化酶组装因子6(COA6), 乳腺癌, 免疫组织化学, 免疫浸润

Abstract: Objective To detect the expression of cytochrome c oxidase assembly factor 6(COA6) in breast cancer, study its clinical significance, and analyze the effect of COA6 on immune infiltration in breast cancer. Methods Differential genes were screened by the whole transcriptome sequencing and the expression of COA6 was explored with TCGA(The Cancer Genome Atlas Program) database. The tissues of 125 breast cancer and adjacent tissues were stained by immunohistochemistry to detect COA6 protein expression and analyze the correlation with clinical features. The COA6 mRNA and protein expression in breast cancer cells and tissues were determined by qRT-PCR and Western blot, respectively. The TIMER(Tumor Immune Estimation Resource) database was used to analyze the correlation between high COA6 gene expression and immune cell infiltration. Results The positive expression rate of COA6 in breast cancer tissues was 88%(110/125), which was higher than that of paracarinoma tissues(7.2%, 9/125)(P＜0.05) and was positively correlated with tumor size and histological grade. In fresh breast cancer tissues, COA6 protein expression was significantly higher than that in adjacent tissues. Both COA6 mRNA and protein expression were significantly increased in the breast cancer cell lines. COA6 was positively correlated with the infiltration of helper T cells, NK cells, CD8⁺ T cells, M1 type macrophages, regulatory T cells, dendritic cells, and memory CD4⁺ T cells in the tumor microenvironment. Conclusions The expression level of COA6 is increased in breast cancer and is positively correlated with tumor immune infiltration, which provides a potential therapeutic target for breast cancer treatment.

Key words: cytochrome c oxidase assembly factor 6(COA6), breast cancer, immunohistochemistry, immune infiltration

中图分类号:

R737.9

金晓霞, 刘玉山, 胡继平, 朱兴华. COA6在乳腺癌中的表达及其与肿瘤免疫细胞浸润相关[J]. 基础医学与临床, 2025, 45(6): 755-761.

JIN Xiaoxia, LIU Yushan, HU Jiping, ZHU Xinghua. Expression of COA6 in breast cancer and its correlation with tumor immune cell infiltration[J]. Basic & Clinical Medicine, 2025, 45(6): 755-761.

参考文献 14

[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135: 584-590.
[2]	Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understandings[J]. J Physiol, 2021, 599: 1745-1757.
[3]	Ghosh P, Vidal C, Dey S, et al. Mitochondria targeting as an effective strategy for cancer therapys[J]. Int J Mol Sci, 2020, 21: 3363. doi: 10.3390/ijms21093363.
[4]	Ashton TM, McKenna WG, Kunz-Schughart LA, et al. Oxidative phosphorylation as an emerging target in cancer therapys[J]. Clin Cancer Res, 2018, 24: 2482-2490.
[5]	Gong Y, Ji P, Yang YS, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targetss[J]. Cell Metab, 2021, 33: 51-64.
[6]	Swaminathan AB, Gohil VM. The role of COA6 in the mitochondrial copper delivery pathway to cytochrome c oxidases[J]. Biomolecules, 2022, 12: 125.doi: 10.3390/biom12010125.
[7]	Baertling F, van den Brand MAM, Hertecant JL, et al. Mutations in COA6 cause cytochrome c oxidase deficiency and neonatal hypertrophic cardiomyopathys[J]. Hum Mutat, 2015, 36: 34-38.
[8]	Luo H, Wang Z. Pan-cancer analysis reveals potential immunological and prognostic roles of COA6 in human cancers and preliminary exploration of COA6 in bladder cancers[J]. Cell Signal, 2024, 117: 111111.doi:10.1016/j.cellsig.2024.111111.
[9]	Zhang M, Liao X, Ji G, et al. High expression of COA6 is related to unfavorable prognosis and enhanced oxidative phosphorylation in lung adenocarcinomas[J]. Int J Mol Sci, 2023, 24: 5705.doi: 10.3390/ijms24065705.
[10]	Zhao X, Chen J, Yin S, et al. The expression of cuproptosis-related genes in hepatocellular carcinoma and their relationships with prognosiss[J]. Front Oncol, 2022, 12: 992468.doi:10.3389/fonc.2022.992468.
[11]	Stroud DA, Maher MJ, Lindau C, et al. COA6 is a mitochondrial complex IV assembly factor critical for biogenesis of mtDNA-encoded COX2[J]. Hum Mol Genet, 2015, 24: 5404-5415.
[12]	Wintjes LTM, Kava M, van den Brandt FA, et al. A novel variant in COX16 causes cytochrome c oxidase deficiency, severe fatal neonatal lactic acidosis, encephalopathy, cardiomyopathy, and liver dysfunctions[J]. Hum Mutat, 2021, 42: 135-141.
[13]	Zahalka AH, Arnal-Estapé A, Maryanovich M, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancers[J]. Science, 2017, 358: 321-326.
[14]	Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironments[J]. Front Immunol, 2018, 9: 3059.doi: 10.3389/fimmu.2018.03059.

[1]	王盟, 沈学静, 刘佳, 尚璐璐, 张沫. 基于探针的无标记表面增强拉曼光谱(SERS)用于鉴别乳腺癌患者的血清代谢谱[J]. 基础医学与临床, 2025, 45(5): 651-657.
[2]	张柯, 陆江宁, 孙立新, 遇珑, 孙力超, 冉宇靓. TOMM40L促进三阴性乳腺癌细胞增殖和迁移并与不良预后相关[J]. 基础医学与临床, 2025, 45(5): 575-582.
[3]	罗钰蓓, 黄建军, 杨文秀, 张军红, 李静, 赵春华, 豆晓伟. 4株患者原代细胞源的乳腺癌细胞系建立及初步研究[J]. 基础医学与临床, 2025, 45(2): 183-188.
[4]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[5]	夏雨佳, 杨振丽, 代娣, 刘玉琴. 乳腺癌类器官的培养及鉴定[J]. 基础医学与临床, 2024, 44(9): 1223-1228.
[6]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[7]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[8]	依合里曼·买买提, 曹燕珍, 王翠翠, 岳娜, 梁莉萍. PIK3CA突变与乳腺癌临床病理特征及预后的相关性[J]. 基础医学与临床, 2024, 44(3): 303-307.
[9]	李欢, 谢贤鑫. circNHSL1通过调控miR-125b-5p/HMGB3轴抑制人乳腺癌细胞系增殖及促凋亡[J]. 基础医学与临床, 2024, 44(12): 1678-1684.
[10]	李江丽, 孙静, 唐一君, 郭君兰, 陈博, 郭胜男. Circ-DDX5靶向miR-3940抑制人乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2024, 44(1): 1-7.
[11]	伊尔夏提·图尔宏, 张海平, 卡吾力·居买, 李子垚, 张力为, 伊地力斯·阿吾提. CST4在哈萨克族食管鳞状细胞癌中的表达及意义[J]. 基础医学与临床, 2023, 43(9): 1412-1416.
[12]	陈宁, 彭甜影, 张伟苗, 高亚诺, 李轩, 闫彩珍, 李军霞. 雷公藤甲素与阿霉素联用对人乳腺癌细胞系 MCF-7 的协同促凋亡作用[J]. 基础医学与临床, 2023, 43(8): 1186-1192.
[13]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[14]	唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.
[15]	金晓霞, 陆晓云, 刘玉山, 梁李娜. SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响[J]. 基础医学与临床, 2023, 43(7): 1090-1096.

COA6在乳腺癌中的表达及其与肿瘤免疫细胞浸润相关

Expression of COA6 in breast cancer and its correlation with tumor immune cell infiltration

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 14

相关文章 15

编辑推荐

Metrics

本文评价